Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

NCT00592007 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Study was terminated due to slow subject accrual

Conditions

Non Small Cell Lung Carcinoma

Interventions

DRUG: Fulvestrant and Erlotinib

Sponsor

Lyudmila Bazhenova, M.D.

Collaborators

[object Object]